Celldex Therapeutics Inc (CLDX)

3.34
0.09 2.60
NASDAQ : Health Care
Prev Close 3.43
Open 3.41
Day Low/High 3.29 / 3.42
52 Wk Low/High 2.96 / 18.62
Volume 870.20K
Avg Volume 2.26M
Exchange NASDAQ
Shares Outstanding 100.55M
Market Cap 349.90M
EPS -1.30
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Celldex Therapeutics (CLDX) Is Strong On High Volume Today

Celldex Therapeutics (CLDX) Is Strong On High Volume Today

Trade-Ideas LLC identified Celldex Therapeutics (CLDX) as a strong on high relative volume candidate

Celldex Reports Second Quarter 2016 Results

Celldex Reports Second Quarter 2016 Results

Conference Call Scheduled for Monday, August 8 at 4:30 p.m. Eastern Time

Celldex To Report Second Quarter 2016 Financial Results And Host Corporate 2016 Objectives Update Call

Celldex To Report Second Quarter 2016 Financial Results And Host Corporate 2016 Objectives Update Call

Conference Call Scheduled for Monday, August 8 at 4:30 p.m. Eastern Time

Celldex Therapeutics Initiates Phase 1/2 Clinical Trial Of New Product Candidate CDX-014 In Advanced Renal Cell Carcinoma

Celldex Therapeutics Initiates Phase 1/2 Clinical Trial Of New Product Candidate CDX-014 In Advanced Renal Cell Carcinoma

Antibody-drug conjugate directed to TIM-1, a novel target upregulated in several cancers

Celldex Therapeutics (CLDX) In A Perilous Reversal

Celldex Therapeutics (CLDX) In A Perilous Reversal

Trade-Ideas LLC identified Celldex Therapeutics (CLDX) as a "perilous reversal" (up big yesterday but down big today) candidate

Celldex Therapeutics (CLDX) Marked As A Dead Cat Bounce Stock

Celldex Therapeutics (CLDX) Marked As A Dead Cat Bounce Stock

Trade-Ideas LLC identified Celldex Therapeutics (CLDX) as a "dead cat bounce" (down big yesterday but up big today) candidate

Celldex Therapeutics' CDX-1401, CDX-301 Combination Generates Potent NY-ESO-1 Immune Responses In Patients With Melanoma

Celldex Therapeutics' CDX-1401, CDX-301 Combination Generates Potent NY-ESO-1 Immune Responses In Patients With Melanoma

CDX-301's utility as a dendritic cell growth factor in combination therapy established

Immunomedics Kicked Out of Prestigious ASCO Cancer Conference

Immunomedics Kicked Out of Prestigious ASCO Cancer Conference

Immunomedics was caught trying to sneak old, previously presented clinical data on its triple-negative breast cancer drug IMMU-132 into the American Society of Clinical Oncology (ASCO) annual meeting.

Celldex Therapeutics (CLDX): Today's Weak On High Volume Stock

Celldex Therapeutics (CLDX): Today's Weak On High Volume Stock

Trade-Ideas LLC identified Celldex Therapeutics (CLDX) as a weak on high relative volume candidate

Great Breadth Fails to Counter Boring Market

This, despite a rare 10-point jump in bulls in the Investors Intelligence readings, which usually occurs in bear markets.

6 Breakout Stocks Under $10 Set to Soar

6 Breakout Stocks Under $10 Set to Soar

These stocks trading for less than $10 a share are within range of triggering breakout trades.

Commit To Buy Celldex Therapeutics At $3, Earn 30% Using Options

Commit To Buy Celldex Therapeutics At $3, Earn 30% Using Options

Investors eyeing a purchase of Celldex Therapeutics, Inc. shares, but tentative about paying the going market price of $4.21/share, might benefit from considering selling puts among the alternative strategies at their disposal.

Celldex Therapeutics (CLDX) Is Today's Strong On High Volume Stock

Celldex Therapeutics (CLDX) Is Today's Strong On High Volume Stock

Trade-Ideas LLC identified Celldex Therapeutics (CLDX) as a strong on high relative volume candidate

Trade-Ideas: Celldex Therapeutics (CLDX) Is Today's

Trade-Ideas: Celldex Therapeutics (CLDX) Is Today's "Perilous Reversal" Stock

Trade-Ideas LLC identified Celldex Therapeutics (CLDX) as a "perilous reversal" (up big yesterday but down big today) candidate

Celldex Therapeutics (CLDX) Weak On High Volume

Celldex Therapeutics (CLDX) Weak On High Volume

Trade-Ideas LLC identified Celldex Therapeutics (CLDX) as a weak on high relative volume candidate

Short Interest In Celldex Therapeutics Increases 12%

Short Interest In Celldex Therapeutics Increases 12%

The most recent short interest data has been released by the NASDAQ for the 03/31/2016 settlement date, which shows a 2,772,151 share increase in total short interest for Celldex Therapeutics, Inc. , to 25,763,736, an increase of 12.06% since 03/15/2016.

Anavex Plays the Orphan Drug Stock Promotion Game

Anavex Plays the Orphan Drug Stock Promotion Game

Too many investors have a fundamental misunderstanding about the significance of orphan drug designation. I should say, insignificance, because the FDA delineation, on its own, means very little.

Trade-Ideas: Celldex Therapeutics (CLDX) Is Today's

Trade-Ideas: Celldex Therapeutics (CLDX) Is Today's "Perilous Reversal" Stock

Trade-Ideas LLC identified Celldex Therapeutics (CLDX) as a "perilous reversal" (up big yesterday but down big today) candidate

Trade-Ideas: Celldex Therapeutics (CLDX) Is Today's Strong On High Relative Volume Stock

Trade-Ideas: Celldex Therapeutics (CLDX) Is Today's Strong On High Relative Volume Stock

Trade-Ideas LLC identified Celldex Therapeutics (CLDX) as a strong on high relative volume candidate

7 Stocks Under $10 to Trade for Breakout Gains

7 Stocks Under $10 to Trade for Breakout Gains

These stocks trading for less than $10 a share are within range of triggering big breakout trades.

Celldex Therapeutics (CLDX) Highlighted As Today's Perilous Reversal Stock

Celldex Therapeutics (CLDX) Highlighted As Today's Perilous Reversal Stock

Trade-Ideas LLC identified Celldex Therapeutics (CLDX) as a "perilous reversal" (up big yesterday but down big today) candidate

6 Biotech Stocks Under $10 to Trade for Big Breakouts

6 Biotech Stocks Under $10 to Trade for Big Breakouts

These stocks trading for less than $10 a share are within range of triggering big breakout trades.